First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)-MedSci.cn

First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Eiger, D; Maurer, C; Brandao, M; Aftimos, PG; Punie, K; Taylor, D; Van den Mooter, T; Poncin, R; Canon, JL; Duhoux, F; Casert, V; Clatot, F; Velghe, C; Craciun, L; Paesmans, M; de Azambuja, E; Ignatiadis, M; Larsimont, D; Piccart, M; Buisseret, L

ANNALS OF ONCOLOGY, 2020; 31 (): S386

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

科室

工具

服务